The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Inclusion criteria

• males or females, aged 18-45
• subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP<140mmHg and 50mmHg ≤DBP<90mmHg;
• body mass index (BMI) between 18 to 28, and a total body weight: male ≥50.0 kg and <90.0 kg; female ≥45.0 kg and <90.0 kg
• Participant in general good health. No clinically significant findings in laboratory parameters or clinically significant abnormality on X-ray

Exclusion criteria

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin > 1X ULN during screening/baseline;
• Abnormal coagulation function;
• A clinical history of coagulation dysfunction；subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.
• Subjects with severe trauma or surgery within 3 months prior to the screening；
• Known blood donation within 30 days pre-dose; donating≥400 ml of blood 3 months pre-dose;
• Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive;
• 3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening;
• Pregnant or Serum β-hCG > 5mIU/mL at baseline or women who are breastfeeding; etc.